alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# Official Journal C 274/2012

| | ISSN 1977-091X
  doi:10.3000/1977091X.C_2012.274.eng |
| --- | --- |
| Official Journal
  of the European Union | C 274 |
| | |
| English edition | Information and Notices | Volume 5511 September 2012 |

ISSN 1977-091X

doi:10.3000/1977091X.C_2012.274.eng

Official Journal

of the European Union

C 274

English edition

Information and Notices

Volume 5511 September 2012

---

| Notice No | Contents | page |
| --- | --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2012/C 274/01 | Euro exchange rates | 1 |

Notice No

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2012/C 274/01

Euro exchange rates

1

---

| | V   Announcements |
| --- | --- |
| | OTHER ACTS |
| | European Commission |
| 2012/C 274/02 | Publication of an amendment application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs | 2 |

V   Announcements

OTHER ACTS

European Commission

2012/C 274/02

Publication of an amendment application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs

2

---

| EN | |
| --- | --- |

EN
Case:17-03283-LTS Doc#:24454 Filed:06/07/23 Entered:06/08/23 12:00:47 Desc: MainDocument Page 1 of 5Case:17-03283-LTS Doc#:24454 Filed:06/07/23 Entered:06/08/23 12:00:47 Desc: MainDocument Page 2 of 5Case:17-03283-LTS Doc#:24454 Filed:06/07/23 Entered:06/08/23 12:00:47 Desc: MainDocument Page 3 of 5Case:17-03283-LTS Doc#:24454 Filed:06/07/23 Entered:06/08/23 12:00:47 Desc: MainDocument Page 4 of 5Case:17-03283-LTS Doc#:24454 Filed:06/07/23 Entered:06/08/23 12:00:47 Desc: MainDocument Page 5 of 5
<TABLE> <S> <C>

<ARTICLE>                     5
<CIK>                                     0000798168
<NAME>                                   JOULE, INC.
<MULTIPLIER>                                   1,000
<CURRENCY>                                       USD

<S>                                              <C>
<PERIOD-TYPE>                                     9-MOS
<FISCAL-YEAR-END>                           SEP-30-1999
<PERIOD-START>                              OCT-01-1998
<PERIOD-END>                                JUN-30-1999
<EXCHANGE-RATE>                                       1
<CASH>                                              240
<SECURITIES>                                          0
<RECEIVABLES>                                    12,054
<ALLOWANCES>                                        338
<INVENTORY>                                           0
<CURRENT-ASSETS>                                 12,110
<PP&E>                                            8,320
<DEPRECIATION>                                    4,234
<TOTAL-ASSETS>                                   17,517
<CURRENT-LIABILITIES>                             9,723
<BONDS>                                               0
<PREFERRED-MANDATORY>                                 0
<PREFERRED>                                           0
<COMMON>                                             38
<OTHER-SE>                                        7,756
<TOTAL-LIABILITY-AND-EQUITY>                     17,517
<SALES>                                               0
<TOTAL-REVENUES>                                 47,900
<CGS>                                                 0
<TOTAL-COSTS>                                    38,790
<OTHER-EXPENSES>                                  7,377
<LOSS-PROVISION>                                     81
<INTEREST-EXPENSE>                                  226
<INCOME-PRETAX>                                   1,426
<INCOME-TAX>                                        535
<INCOME-CONTINUING>                                 891
<DISCONTINUED>                                        0
<EXTRAORDINARY>                                       0
<CHANGES>                                             0
<NET-INCOME>                                        891
<EPS-BASIC>                                       .24
<EPS-DILUTED>                                       .24


</TABLE>
§ 25.203 Stall characteristics. ( a ) It must be possible to produce and to correct roll and yaw by unreversed use of the aileron and rudder controls, up to the time the airplane is stalled. No abnormal nose-up pitching may occur. The longitudinal control force must be positive up to and throughout the stall. In addition, it must be possible to promptly prevent stalling and to recover from a stall by normal use of the controls.
( b ) For level wing stalls, the roll occurring between the stall and the completion of the recovery may not exceed approximately 20 degrees.
( c ) For turning flight stalls, the action of the airplane after the stall may not be so violent or extreme as to make it difficult, with normal piloting skill, to effect a prompt recovery and to regain control of the airplane. The maximum bank angle that occurs during the recovery may not exceed— ( 1 ) Approximately 60 degrees in the original direction of the turn, or 30 degrees in the opposite direction, for deceleration rates up to 1 knot per second; and
( 2 ) Approximately 90 degrees in the original direction of the turn, or 60 degrees in the opposite direction, for deceleration rates in excess of 1 knot per second.
[Doc. No. 5066, 29 FR 18291, Dec. 24, 1964, as amended by Amdt. 25-84, 60 FR 30750, June 9, 1995]
EX-10.8



	




Exhibit 10.8  




 




BIOCRYST PHARMACEUTICALS,
INC.
2190 PARKWAY LAKE DRIVE 
BIRMINGHAM, AL 35244
205-444-4600    205-444-4640 FAX

www.biocryst.com 



July 10, 2002 



MEMORANDUM 










	TO:  	BioCryst
Compensation Committee 






	FROM:  	Charlie
Bugg and Claude Bennett 






	SUBJECT:  	Salary
reductions 






	

     




        Considering
the deep cuts that we have made in personnel at BioCryst, we feel that it would be
appropriate for us to reduce our current salaries by 25%. The Compensation Committee will
consider appropriate readjustments of our salaries when the financial condition of the
company improves. The cumulative salary cuts would be repaid to us in the event of a
change-of-control of the company. 




/s/ Charles E. Bugg
———————————————

Charles E. Bugg
Chairman & Chief Executive Officer 




/s/ J. Claude Bennett
———————————————
J. Claude Bennett
President
& Chief Operating Officer 



Agreed –
Compensation Committee: 




/s/ William W.
Featheringill
———————————————
William W. Featheringill 




/s/ Edwin A. Gee
———————————————

Edwin A. Gee 




/s/ William M. Spencer,
III 
———————————————

William M. Spencer, III 




22
UNITED STATES DISTRICT COURT

DISTRICT OF PUERTO RICO

PROMESA

Title III

No. 17-BK-3283 (LTS)

(Jointly Administered)

NOTICE OF WITHDRAWAL OF MOTION BY VIRGILIO F. ACEVEDO FOR 

RELIEF FROM AUTOMATIC STAY (Docket #3163)

Respectfully Submitted by

Virgilio F. Acevedo 

Through Counsel of Record

/s/Carmenelisa Perez-Kudzma

Perez-Kudzma Law Office, 

P.C. 413 Boston Post Road 

Weston, MA 02493 

978-505-3333 

carmenelisa@pklaw.law 

Attorney for Virgilio F. Acevedo

In re:

THE FINANCIAL OVERSIGHT AND

MANAGEMENT BOARD FOR

PUERTO RICO

as representative of 

THE COMMONWEALTH OF PUERTO 

RICO, et al.

Debtor 

1 

Now Comes Virgilio F. Acevedo and hereby notices the withdrawl of his motion for relief (docket 

#3163) as the Parties have resolved the matter by means of a stipulation. 

June 29, 2018

Case:17-03283-LTS Doc#:3388 Filed:06/29/18 Entered:06/29/18 16:31:48 Desc: Main

Document Page 1 of 2
CERTIFICATE OF SERVICE

I hereby certify that, on, June 29, 2018 I electronically filed the foregoing with the 

Clerk of the Court using the CM/ECF system, which will send notification of such filing 

to all counsel of record and parties in the Master Service List. The foregoing is also being 

mailed separately to (1) Wanda Vázquez Garced, Secretary of Justice, Department of 

Justice, Apartado 9020192, San Juan, PR 00902-0192; and (2) Regsitrar Gildren S. 

Caro Pérez, Registry of Deeds of Aguadilla, PO Box 447, Aguadilla, PR 00605.

18

/s/Carmenelisa Perez-Kudzma

Case:17-03283-LTS Doc#:3388 Filed:06/29/18 Entered:06/29/18 16:31:48 Desc: Main

Document Page 2 of 2
[Federal Register Volume 65, Number 84 (Monday, May 1, 2000)]
[Notices]
[Page 25341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-10792]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel, ZDK1 GRB-1 M1 P.
    Date: April 26, 2000.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott, 2899 Jefferson Davis Highway, 
Arlington, VA 22203.
    Contact Person: Carolyn Miles, PhD, Scientific Review 
Administrator, Review Branch, DEA, NIDDK, Room 641, 6707 Democracy 
Boulevard, National Institutes of Health, Bethesda, MD 20892, (301) 
594-7791.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel, ZDK1 GRB-1 (M4).
    Date: May 11, 2000.
    Time: 9:30 a.m. to 11:30 a.m.
    Agenda: To review and evaluate grant applications.
    Place: 6707 Democracy Blvd, Two Democracy Plaza, 6th Floor, Room 
641, MSC 5452, Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Carolyn Miles, PhD, Scientific Review 
Administrator, Review Branch, DEA, NIDDK, Room 641, 6707 Democracy 
Boulevard, National Institutes of Health, Bethesda, MD 20892, (301) 
594-7791.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: April 24, 2000.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 00-10792 Filed 4-28-00; 8:45 am]
BILLING CODE 4140-01-M
§ 121.543 Flight crewmembers at controls. ( a ) Except as provided in paragraph (b) of this section, each required flight crewmember on flight deck duty must remain at the assigned duty station with seat belt fastened while the aircraft is taking off or landing, and while it is en route.
( b ) A required flight crewmember may leave the assigned duty station— ( 1 ) If the crewmember's absence is necessary for the performance of duties in connection with the operation of the aircraft;
( 2 ) If the crewmember's absence is in connection with physiological needs; or
( 3 ) If the crewmember is taking a rest period, and relief is provided— ( i ) In the case of the assigned pilot in command during the en route cruise portion of the flight, by a pilot who holds an airline transport pilot certificate not subject to the limitations in § 61.167 of this chapter and an appropriate type rating, is currently qualified as pilot in command or second in command, and is qualified as pilot in command of that aircraft during the en route cruise portion of the flight. A second in command qualified to act as a pilot in command en route need not have completed the following pilot in command requirements: The 6-month recurrent flight training required by § 121.433(c)(1)(iii); the operating experience required by § 121.434; the takeoffs and landings required by § 121.439; the line check required by § 121.440; and the 6-month proficiency check or simulator training required by § 121.441(a)(1); and
( ii ) In the case of the assigned second in command, by a pilot qualified to act as second in command of that aircraft during en route operations. However, the relief pilot need not meet the recent experience requirements of § 121.439(b).
[Doc. No. 16383, 43 FR 22648, May 25, 1978, as amended by Amdt. 121-179, 47 FR 33390, Aug. 2, 1982; Amdt. 121-365, 78 FR 42378, July 15, 2013]
#### § 25.833 Combustion heating systems.

Combustion heaters must be approved.

[Amdt. 25-72, 55 FR 29783, July 20, 1990]
EXHIBIT 41.1
                                  ------------

CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

We hereby  consent  to the  incorporation  of our  report  dated  May 12,  2005,
included in this Form 10-KSB in the previously filed Registration  Statements of
Legend Mobile,  Inc.  (formerly PTN Media,  Inc.) and  subsidiaries  on Form S-8
(File  No.  333-80771,  333-63174  and  333-112061)  and on Form S-3  (File  No.
333-51600 and 333-64328).



/s/  E. Randall Gruber, CPA, PC


                                  End of Filing
EXHIBIT A 

Schedule of Claims Subject to Five Hundred Eighty-Fourth Omnibus Objection 

 

Case:17-03283-LTS Doc#:24762-1 Filed:07/14/23 Entered:07/14/23 21:17:50 Desc:

Exhibit Claim Subject to the 584 Omnibus English Page 1 of 2
CLAIM 

CLAIM # AMOUNT

CASE NUMBER / 

DEBTOR

DATE 

NAME FILED

CLAIMS TO BE DISALLOWED REMAINING AMENDED CLAIMS

Five Hundred Eighty-Fourth Omnibus Objection

Exhibit A - Claims to Be Disallowed

CLAIM 

CLAIM # AMOUNT

CASE NUMBER / 

DEBTOR

DATE 

NAME FILED

 1 03/28/23 17 BK 03283-LTS

Commonwealth of 

Puerto Rico

MANPOWERGROUP, 180870 $875,000.00

INC.

C/O KOHNER, MANN 

& KAILAS, S.C.

4650 NORTH PORT 

WASHINGTON RD.

MILWAUKEE, WI 

53212

MANPOWERGROUP, 

INC.

C/O KOHNER, MANN 

& KAILAS, S.C.

4650 NORTH PORT 

WASHINGTON RD.

MILWAUKEE, WI 53212

04/19/23 17 BK 03283-LTS

Commonwealth of Puerto 

Rico

180866 $875,000.00

Reason: Amended and superseded by a later filed Proof of Claim.

 2 03/20/23 17 BK 03283-LTS

Commonwealth of 

Puerto Rico

QUEST DIAGNOSTICS 180865 $350,000.00

OF PUERTO RICO, 

INC.

FAEGRE DRINKER 

BIDDLE & REATH 

LLP

BRETT D. FALLON

222 DELAWARE 

AVENUE, SUITE 1410

WILMINGTON, DE 

19801

QUEST DIAGNOSTICS 

OF PUERTO RICO, INC.

FAEGRE DRINKER 

BIDDLE & REATH LLP

BRETT D. FALLON

222 DELAWARE 

AVENUE, SUITE 1410

WILMINGTON, DE 

19801

04/10/23 17 BK 03283-LTS

Commonwealth of Puerto 

Rico

180867 $350,000.00

Reason: Amended and superseded by a later filed Proof of Claim.

1

Case:17-03283-LTS Doc#:24762-1 Filed:07/14/23 Entered:07/14/23 21:17:50 Desc:

Exhibit Claim Subject to the 584 Omnibus English Page 2 of 2
EXHIBIT 32.1

CERTIFICATION PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 

RULE 13a-14(b) OR 15d-14(b) AND 

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO 

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Jurak CorporationWorld Wide, Inc. (the "Company") on Form 10-KSB for year ended May 31, 2006, asfiled with the Securities and Exchange Commission of the date hereof, I, AnthonyC. Jurak, Chairman of the Board and Director and Chief Executive Officer of theCompany, certify for the purpose of complying with Rule 13a-14(b) or Rule15d-14(b) of the Securities Exchange Act of 1934 (the "Exchange Act') andSection 1350 of Chapter 63 of Title 18 of the United States Code, that: 

(1) the Company's Annual Report fully complies with the      requirements of Section 13(a) or 15(d) of the Securities Exchange Act of      1934; and

(2) the information contained in the Annual Report      fairly presents, in all material respects, the financial condition and      results of operations of the Company.

Date: September 12, 2006

 

/s/ Anthony C. Jurak

-------------------------------

Anthony C. Jurak

Chairman of the Board and Director

Chief Executive Officer and ChiefFinancial Officer
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                       3,643,000
<SECURITIES>                                         0
<RECEIVABLES>                                1,035,000
<ALLOWANCES>                                   (36,000)
<INVENTORY>                                          0
<CURRENT-ASSETS>                             4,894,825
<PP&E>                                       2,399,000
<DEPRECIATION>                                (474,710)
<TOTAL-ASSETS>                               7,200,000
<CURRENT-LIABILITIES>                        2,257,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     5,700,000
<OTHER-SE>                                  (2,978,000)
<TOTAL-LIABILITY-AND-EQUITY>                 7,200,000
<SALES>                                     12,897,000
<TOTAL-REVENUES>                            12,897,000
<CGS>                                        3,389,000
<TOTAL-COSTS>                               15,025,000
<OTHER-EXPENSES>                                (1,000)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             155,000
<INCOME-PRETAX>                             (2,282,000)
<INCOME-TAX>                                   104,000
<INCOME-CONTINUING>                         (2,386,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (2,386,000)
<EPS-BASIC>                                      (0.21)
<EPS-DILUTED>                                    (0.21)


</TABLE>
[Federal Register Volume 65, Number 86 (Wednesday, May 3, 2000)]
[Rules and Regulations]
[Pages 25641-25642]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-10932]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 510


New Animal Drugs; Change of Sponsor's Name and Address

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect a change of sponsor's name and address for 
Global Pharmaceutical Corp.

DATES: This rule is effective May 3, 2000.

FOR FURTHER INFORMATION CONTACT: Thomas J. McKay, Center for Veterinary 
Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855, 301-827-0213.

SUPPLEMENTARY INFORMATION: Global Pharmaceutical Corp., Castor and 
Kensington Aves., Philadelphia, PA 19124, has informed FDA of a change 
of sponsor's name and address to IMPAX Laboratories, Inc., 30831 
Huntwood Ave., Hayward, CA 94544. Accordingly, the agency is amending 
the regulations in 21 CFR 510.600(c)(1) and (c)(2) to reflect the 
change of sponsor's name and address.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

[[Page 25642]]

List of Subjects in 21 CFR Part 510

    Administrative practice and procedure, Animal drugs, Labeling, 
Reporting and recordkeeping requirements.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is 
amended as follows:

PART 510--NEW ANIMAL DRUGS

    1. The authority citation for 21 CFR part 510 continues to read as 
follows:

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.


Sec. 510.600  [Amended]

    2. Section 510.600 Names, addresses, and drug labeler codes of 
sponsors of approved applications is amended in the table in paragraph 
(c)(1) by removing the entry for ``Global Pharmaceutical Corp.'' and by 
alphabetically adding an entry for ``IMPAX Laboratories, Inc., 30831 
Huntwood Ave., Hayward, CA 94544''; and in the table in paragraph 
(c)(2) in the entry for ``000115'' by removing the sponsor name and 
address and by adding their place ``IMPAX Laboratories, Inc., 30831 
Huntwood Ave., Hayward, CA 94544.

    Dated: April 24, 2000.
Claire M. Lathers,
Director, Office of New Animal Drug Evaluation, Center for Veterinary 
Medicine.
[FR Doc. 00-10932 Filed 5-2-00; 8:45 am]
BILLING CODE 4160-01-F
§ 347.304 Accounting for fees on international loans. ( a ) *Restrictions on fees for restructured international loans.* No banking institution shall charge, in connection with the restructuring of an international loan, any fee exceeding the administrative cost of the restructuring unless it amortizes the amount of the fee exceeding the administrative cost over the effective life of the loan.
( b ) *Accounting treatment.* Subject to paragraph (a) of this section, banking institutions shall account for fees on international loans in accordance with generally accepted accounting principles.
EXHIBIT A 

Case:17-03283-LTS Doc#:2948-1 Filed:04/23/18 Entered:04/23/18 18:55:40 Desc:

Exhibit A Page 1 of 2
 

Exhibit A – Fiscal Plan Development Materials 

1. 1.2.6 

2. 2.8.3.1 

3. 2.8.4.1 

4. 2.8.4.2 

5. 4.10.3.3.529 

6. 4.10.3.3.546 

7. 4.11.2.3 

Case:17-03283-LTS Doc#:2948-1 Filed:04/23/18 Entered:04/23/18 18:55:40 Desc:

Exhibit A Page 2 of 2
EXHIBIT 32.1    Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Peter Klamka, the Principal Executive Officer and Principal Financial Officer of Bitcoins Brands Inc. (the "Company"), hereby certify, that, to my knowledge:  1. The Annual Report on Form 10-K for the year ended December 31, 2013 (the "Report") of the Company fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the year ended December 31, 2013.   Date: March 19, 2015By:/s/ Peter KlamkaName: Peter KlamkaTitle: Chief Executive Officer and Chief Financial Officer